Researchers receive $9M NCI grant for imaging tech in clinical trials

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.

March 07, 2025

Vol.51 No.09

In Brief

UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

The University of Hawai‘i Cancer Center and the Queen’s Health Systems will jointly develop oncology clinic space at the UH Cancer Center’s facilities in Kaka‘ako.

February 28, 2025

Vol.51 No.08

Drugs & Targets

DeepHealth, TeraRecon announce collaboration around integrated AI and advanced visualization

DeepHealth and ConcertAI’s TeraRecon announced a strategic collaboration to integrate certain capabilities to advance imaging tools and the radiology workflow.

February 28, 2025

Vol.51 No.08

Clinical Roundup

Cortechs.ai, EDAP TMS announce OnQ prostate-assisted robotic HIFU procedure

Cortechs.ai and EDAP TMS SA announced the successful completion of the world’s first OnQ Prostate-assisted Focal One Robotic HIFU procedure at the University of California, San Francisco Prostate Center.

February 14, 2025

Vol.51 No.06

Clinical Trials & Tribulations

Physicians and biopharma should improve accessibility of cancer trials

Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.

Dual-targeted therapies + chemo shows high response rates in BRAF-mutated metastatic CRC, phase III trial shows

Patients with metastatic colorectal cancer harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies Braftovi(encorafenib) and Erbitux(cetuximab) plus a mFOLFOX6 chemotherapy regimen, according to results from the phase III BREAKWATER trial led by researchers at the University of Texas MD Anderson Cancer Center.

January 31, 2025

Vol.51 No.04